Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 12,402 $ 9,589
Marketable securities, current 21,189 39,091
Collaboration receivable 921 1,891
Prepaid expenses and other current assets 1,294 2,599
Total current assets 35,806 53,170
Property and equipment, net 208 333
Other assets 166 166
Total assets 36,180 53,669
Current liabilities:    
Accounts payable 3,076 725
Accrued clinical and development expenses 2,097 6,834
Accrued liabilities 616 3,269
Total current liabilities 5,789 10,828
Warrant liability 2,490 1,864
Deferred rent 87 131
Total liabilities 8,366 12,823
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 71,511,425 shares at June 30, 2016 and 71,462,059 shares at December 31, 2015 72 71
Additional paid-in capital 371,893 370,236
Accumulated other comprehensive loss 5 (21)
Accumulated deficit (344,156) (329,440)
Total stockholders’ equity 27,814 40,846
Total liabilities and stockholders’ equity $ 36,180 $ 53,669